Association of anti-inflammatory cytokine IL10 polymorphisms with motoric cognitive risk syndrome in an Ashkenazi Jewish population

Abstract

Motoric cognitive risk (MCR) syndrome is a newly described predementia syndrome characterized by the presence of cognitive complaints and slow gait, which is associated with increased risk of conversion to dementia. The underlying biological mechanisms for MCR have not yet been established. Neuroinflammation mediated through cytokines plays a pivotal role in the pathogenesis of dementia. Hence, our objective was to prospectively examine whether variations in cytokine genes (CRP, IFNG, IL1A, IL1B, IL4, IL6, IL10, IL18, TNF, and IL12A) play a role in MCR incidence in 530 community-dwelling Ashkenazi Jewish adults aged 65 years and older without MCR or dementia at baseline enrolled in the LonGenity study. Over a median follow-up of 2.99 years, 70 participants developed MCR. Single nucleotide polymorphisms (SNPs) in the transcriptional regulatory regions of cytokine IL10, rs1800896 (hazard ratio adjusted for age, gender, and education, aHR: 1.667; 95% CI: 1.198–2.321) and rs3024498 (aHR: 1.926; 95% CI: 1.315–2.822), were associated with incident MCR. Functional analysis using in silico approaches indicated associated SNP rs3024498 “C” allele being the local expression quantitative trait locus. Associated alleles of both the SNPs, rs1800896 and rs3024498, were implicated with overexpression of IL10 gene. None of the variants in the neuroinflammatory pathway studied were associated with incident mild cognitive impairment syndrome. These observations support a role for the IL10 gene in dementia pathogenesis by increasing risk of developing MCR in older adults.

Introduction

Inflammation mediated through proinflammatory and anti-inflammatory cytokines is postulated to play a pivotal role in the pathogenesis of dementia syndromes such as Alzheimer's disease (AD) as well as vascular dementia in older adults (Akiyama et al., 2000, Cacquevel et al., 2004, Heneka et al., 2015, Rogers et al., 1996). Expression studies show significant differences in cytokine profiles in AD and vascular dementia; a meta-analysis of 40 studies of cytokines in AD patients found higher serum concentrations of interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), IL-1β, IL-12, and IL-18 in these individuals compared to healthy controls (Swardfager et al., 2010). Accumulation of macrophage like cells in the brain (microglia) around amyloid β-plaques is a hallmark of AD (Thériault et al., 2015). Binding of amyloid β to the microglia induces expression of proinflammatory cytokines namely IL-1β, TNFα, IL-6, and IL-18 (Wang et al., 2015). Furthermore, inflammatory mediators produced by microglia play a role in increasing the production of amyloid β precursor protein (APP) and its conversion to Aβ-42 protein (Heneka et al., 2015), which leads to worsening cognitive status. Overexpression of IL-1β, TNFα, and IL-6 was reported in vascular dementia patients (Wada-Isoe et al., 2004, Zuliani et al., 2007). Inflammation and oxidative stress play a significant role in neurovascular dysfunction leading to hypoxia or ischemia and contributing to cognitive impairment in vascular dementia (Iadecola, 2013).

Genetic association studies also point toward the key role of proinflammatory and anti-inflammatory cytokine genes in dementia pathogenesis (McGeer and McGeer, 2001, Mun et al., 2016). Genetic variants in IL1A, IL1B, IL6, TNF, IL10, TGFB, IL1RN, IL18, and IL8 in the inflammatory pathway are the most studied in this context and were associated with dementia (Bertram and Tanzi, 2011, Bertram et al., 2007, Di Bona et al., 2008, Di Bona et al., 2012, Li et al., 2013, Qi et al., 2012). More importantly, these studies have shown association with the genetic variants in the regulatory regions, mainly promoters of these genes (Bertram and Tanzi, 2011, Bertram et al., 2007, Di Bona et al., 2008, Di Bona et al., 2012, Li et al., 2013, Qi et al., 2012). Promoter region polymorphisms -889C/T (rs1800587) in IL1A (Li et al., 2013), -174G/C (rs1800795), -572C/G (rs1800796), and -597G/A (rs1800797) in IL6 (Dai et al., 2012, Qi et al., 2012) as well as -308 G/A (rs1800629) in TNFA and -1082 A/G (rs1800896) in IL10 gene (Di Bona et al., 2012) are associated with dementia. These observations point toward possible regulatory mechanisms involved at the genetic level in the expression of these genes, which might be controlled by other risk factors associated with dementia.

Motoric cognitive risk (MCR) syndrome is a predementia syndrome in older individuals that is characterized by presence of cognitive complaints and slow gait (Verghese et al., 2013, Verghese et al., 2014a). Individuals with MCR are at high risk for transitioning to dementia, both AD (Verghese et al., 2014a) and vascular dementia (Verghese et al., 2013) even after accounting for other established dementia risk factors as well as overlap with other predementia syndromes such as the mild cognitive impairment syndrome (MCI) (Verghese et al., 2014a). MCR is common in older populations; a pooled analysis of 26,802 older adults from 17 countries showed a prevalence of MCR of 9.7% (Verghese et al., 2014a). An age- and sex- adjusted incidence of MCR of 65.2/1000 person years was reported in 4 US-based cohorts (Verghese et al., 2014b).

As MCR was described recently, the underlying biology has not yet been established. Elevated levels of inflammatory markers have been linked to risk of developing the main components of MCR; cognitive complaints (McAfoose and Baune, 2009, Trollor et al., 2012, Wilson et al., 2002) as well as slow gait (Verghese et al., 2011). Hence, we hypothesized that inflammatory gene variants would increase the risk of developing MCR in older adults. To examine the role of inflammatory pathways in the pathogenesis of MCR, we conducted a prospective cohort study in 530 community-residing Ashkenazi Jewish (AJ) seniors participating in the LonGenity Study (Eny et al., 2014, Roshandel et al., 2016). Establishing biological underpinnings of the MCR syndrome may provide new insights into preventive strategies to reduce the burden of dementia.